🔗 Share this article

As the United States undertakes historic changes to its vaccine recommendations, an unexpected name appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid vaccines in the pandemic and has concentrated on possible fatalities following Covid vaccination in her brief tenure at the FDA.

Scheduled Changes to Childhood Immunization Schedule

Health officials had intended to unveil major changes to the pediatric immunization program earlier this month, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with many the world with no evidence for public health gain. The announcement has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

A Shift at the Agency

The acting appointment could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US to become more like Denmark, a society with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Background

Høeg has little discernible track record in drug development, oversight or leadership, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She lacks experience in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “understand regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Clearly, she has not acquired the type of experience that former directors who headed the center have had.”

The drug center has an immense range of responsibilities at the agency, Woodcock pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic drug division clears numerous generic medications. There is also a biosimilars division, OTC medication office and so forth, and each of these have to be managed,” Dr. Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the position, which supervises over 5,000 personnel. “It is a huge leadership role, if you execute it properly,” the former official said.

Response and Disputed Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this assignment represents greater collaboration among agency officials on immunizations, a press secretary said that the “inquiries rely on flawed presumptions”.

“Her resume matches the functions of her role,” the representative explained, citing the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious one-day medication authorization process that reportedly concerned her former heads. “By what process are these medications being picked for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards more relaxed oversight of most medications, aside from shots.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if concerning, track record, some experts have noted. She authored a analysis using unconfirmed volunteer-provided data to determine the rate of heart inflammation after Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccines are more dangerous than they are.

Among her “desired changes” for the new administration encompassed changing regulations for novel immunizations and discontinuing “unnecessary” immunizations, she said after the election on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of barring young men from receiving COVID-19 vaccines.

“She is an all-around true believer who begins with her conclusions and works backwards to fit the science in a highly deceptive, untruthful way,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|